ACSL1 has an overall AD Target Risk Score among the top 5% of all scored targets (score 3.72, rank #1,040) and has been nominated by AMP-AD investigators as a candidate therapeutic target in AD. This evidence concerns the gene ACSL1 and Alzheimer disease.